ClinicalTrials.gg
RecruitingNCT06641466Updated Jul 9, 2026

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

A Phase 3 interventional study of Rimegepant and Placebo Comparator in Menstrual Migraine, sponsored by Pfizer. Recruiting at 123 sites in 15 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
723
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Planned enrollment
14th of 32
723 · median 618
Started
2025
with 4 others
Phase 3
14 of 32
5 open now
Primary completion
2026-11
later than 3 of 14 live
Registered
22nd of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 14th largest by planned enrollment, is one of 5 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 3 of the 14 other live ones, and was the 22nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

03

Conditions studied

  • Menstrual Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has regular menstrual cycles ≥24 days and ≤34 days
  2. A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition
  3. A history of menstrual migraine attacks of at least 3 months
  4. Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.
  5. If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study

Exclusion criteria

Exclusion Criteria:

  1. Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening
  2. A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening
  3. History of retinal migraine, basilar migraine or hemiplegic migraine
  4. Current diagnosis of schizophrenia, bipolar, or borderline personality disorder
  5. Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
723 participants (estimated)

Study arms

  • Experimental
    Rimegepant 75 mg Orally Disintegrating Tablet (ODT) 7-Day Dosing

    Drug: Rimegepant

  • Experimental
    Rimegepant 75 mg Orally Disintegrating Tablet (ODT) Acute Treatment Dosing

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Drug: Placebo Comparator

  • Active comparator
    Standard of Care

    Drug: Standard of Care

Interventions

  • Rimegepant 75 mg ODT for 7 days

  • DrugPlacebo Comparator

    Matching placebo oral disintegrating tablets for 7 days

  • DrugStandard of Care

    Standard of care for acute treatment as needed

  • Rimegepant 75 mg ODT for acute treatment as needed

06

What researchers measure

Primary outcomes

  1. Mean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from Observation Period in the number of migraine days per the 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

Secondary outcomes

  1. Mean change from the Observation Period in number of headache days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Period in number of headache days per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  2. Percentage of participants with ≥50% reduction from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase (50% responder)

    Patients with ≥50% reduction from the Observation Period in number of migraine days per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  3. Mean change from the Observation Period in number of acute migraine medication days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Period in number of acute migraine medication days per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  4. Mean change from the Observation Period in number of acute migraine-specific medication days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Period in number of acute migraine specific medication days per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  5. Mean change from the Observation Period in number of migraine days with moderate-severe functional disability per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Period in number of migraine days with moderate-severe functional disability per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  6. Mean change from the Observation Period in number of moderate-severe headache days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Period in number of moderate-severe headache days per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  7. Mean change from the Observation Period in number of moderate-severe migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Phase in number of moderate-severe migraine days per 5-day perimenstrual period

    Time frame: 5 months (5 menstrual cycles)

  8. Mean change from baseline in the MiCOAS Cognition score at postdosing (ie, 1 day after the 7-day dosing period) across each cycle of the Double-Blind Treatment Phase

    Change from baseline in the MiCOAS Cognition score at post-dosing across each cycle

    Time frame: 5 months (5 menstrual cycles)

  9. Mean change from the Observation Period in monthly migraine days (per cycle, normalized to 28-days) across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Phase in monthly migraine days

    Time frame: 5 months (5 menstrual cycles)

  10. Mean change from the Observation Period in monthly headache days (per cycle, normalized to 28-days) across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Phase in monthly headache days

    Time frame: 5 months (5 menstrual cycles)

  11. Mean change from the Observation Phase in monthly acute migraine-specific medication days (per cycle, normalized to 28-days) across each cycle of the Double-Blind Treatment Phase

    Change from the Observation Phase in monthly acute migraine-specific medication days

    Time frame: 5 months (5 menstrual cycles)

07

Study locations

123 of 123 sites recruiting

Showing the first 100 of 123 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 20 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 15, 2024
StartActual
Mar 11, 2025
Primary completionEst.
Nov 29, 2026
CompletionEst.
Mar 30, 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06641466
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Mar 11, 2025
Primary completion
Nov 29, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion